Key result
Statins drive a dose-dependent increase in new-onset diabetes without clear evidence for neuropsychiatric harm.
Why the study?
Do statins and cholesterol-lowering drugs cause cardiovascular costs and neuropsychiatric effects in the expanded eligible population?
Do statins and cholesterol-lowering drugs cause cardiovascular costs and neuropsychiatric effects in the expanded eligible population?
Answers are grounded in this paper and cite their sources.
This independent synthesis argues that lowering cholesterol thresholds expanded statin eligibility to lower-risk populations where the harms, such as new-onset diabetes, may outweigh the modest absolute benefits.
Standalone investigative research preprint. Diagnostic thresholds for “high cholesterol” have been revised downward repeatedly since 1987, and eligibility for cholesterol-lowering drug therapy shifted in 2013 from a fixed-lipid model to a risk-score model that further expanded the treated population. Population cholesterol levels have fallen or held flat over the same period, meaning growth in diagnosis and treatment is substantially a function of moving goalposts and expanded screening rather than a worsening underlying epidemic. This paper traces that threshold history, quantifies the population it manufactured (~12.8 million newly eligible US adults under the 2013 ACC/AHA guideline), and evaluates two downstream questions with the best available causal-inference evidence: (1) whether the drugs prescribed to this manufactured population carry cardiovascular costs (via new-onset diabetes and other flow-on effects) that are systematically under-weighted against their modest absolute benefit; and (2) whether cholesterol-lowering drugs have measurable, mischaracterized effects on the brain. Headline findings (internal evidence tiers): Guideline-driven manufactured patient population, shaped by undisclosed panel financial conflicts of interest: [ESTABLISHED] via triangulation. Statins cause a dose-dependent increase in new-onset type 2 diabetes: [ESTABLISHED] via Bradford Hill + triangulation. Aggregate claim that statins caused rising heart-disease mortality: not supported (mortality fell throughout the statin era). Net harm in the specific low-risk subgroup created by threshold-lowering: [MODERATE] (single microsimulation). Brain/CNS effects: [CONTESTED] — genuine split across RCTs, pharmacovigilance, and Mendelian randomization, with the largest available MR study (N>1 million) leaning toward reassurance on dementia specifically. Not medical advice. This document is an independent research synthesis. It is not a clinical guideline and must not be used to start, stop, or change any medication. Readers taking a statin or other cholesterol-lowering drug should discuss questions with their own physician before making any treatment decision. Several findings in this paper specifically caution against unsupervised statin discontinuation. Licence and invitation to reuse (CC0 1.0 Universal). No rights reserved. Any researcher, clinician, journalist, or academic may copy, adapt, extend, correct, or republish any part of this work — including under their own name — without asking permission and without attribution being required or expected. If you find an error, a stronger source, or a better method, the appropriate response is to fix it and publish the correction. The intent is that the ideas and evidence assembled here should be picked up, tested, and improved by anyone with the standing and expertise to take them further. AI assistance disclosure. This manuscript is an AI-assisted research synthesis, prepared with large language model assistance and offered freely under CC0 as a starting point for independent academic verification and adoption. It has not been peer-reviewed. Every claim, figure, and citation should be independently re-verified by anyone adopting or citing this work. A detailed reference and fact-check log is included as an appendix in the PDF. Files: (1) PDF — typeset full paper including reference/fact-check appendix; (2) Markdown source (prefixed zzz_ so it sorts last) — canonical editable source.
No takes yet. Share an insight, caveat, or question.
Marcus Webb (2026) conducted a review in High cholesterol. Statins and cholesterol-lowering drugs was evaluated. Statins cause a dose-dependent increase in new-onset type 2 diabetes, while evidence for neuropsychiatric effects remains contested and claims of rising heart-disease mortality are unsupported.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: